Dendritic cells in the cancer microenvironment

Journal of Cancer

Volumn 4, Issue 1, 2013, Pages 36-44

  Ma, Yang ^a   Shurin, Galina V ^a   Peiyuan, Zhu ^b   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Dendritic cells; Immunosuppression; Regulatory dendritic cells; Tumor escape.; Tumor microenvironment

Indexed keywords

GANGLIOSIDE; INTERLEUKIN 10; INTERLEUKIN 12; NEUROPEPTIDE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; BREAST CANCER; CARCINOGENIC ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; DENDRITIC CELL; EFFECTOR CELL; ENDOMETRIOID CARCINOMA; HUMAN; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; LUNG CANCER; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OVARY CANCER; PHENOTYPE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

EID: 84880922175     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5046     Document Type: Review

References (96)

1. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996; 43: 158-64.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
3. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445-9.
4. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80: 477-83.
5. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev 2011; 241: 206-27.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
7. Bjorck P, Leong HX, Engleman EG. Plasmacytoid dendritic cell dichotomy: identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset. J Immunol 2011; 186: 1477-85.
8. Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol 2011; 11: 558-65.
9. Vermi W, Soncini M, Melocchi L, Sozzani S, Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011; 90: 681-90.
10. Lin A, Schildknecht A, Nguyen LT, Ohashi PS. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett 2010; 127: 77-84.
11. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL. Intratumoral cytokines/ chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006; 25: 333-56.
12. Shurin MR. Cancer as an immune-mediated disease. Immuno Targets and Therapy 2012; in press.
13. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997; 226: 1-5.
14. Poppema S, Brocker EB, de Leij L, Terbrack D, Visscher T, Ter Haar A, Macher E, The TH, Sorg C. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 1983; 51: 77-82.
15. Nestor MS, Cochran AJ. Identification and quantification of subsets of mononuclear inflammatory cells in melanocytic and other human tumors. Pigment Cell Res 1987; 1: 22-7.
16. Lijun Z, Xin Z, Danhua S, Xiaoping L, Jianliu W, Huilan W, Lihui W. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int J Gynecol Cancer 2012; 22: 836-41.
17. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91: 2136-47.
18. Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfeld RA, Becker JC. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14: 111-21.
19. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207: 1791-804.
20. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-7.
21. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Timar J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56: 1459-69.
22. Gatter KC, Morris HB, Roach B, Mortimer P, Fleming KA, Mason DY. Langerhans' cells and T cells in human skin tumours: an immunohistological study. Histopathology 1984; 8: 229-44.
23. Facchetti F, de Wolf-Peeters C, de Greef H, Desmet VJ. Langerhans cells in various benign and malignant pigment-cell lesions of the skin. Arch Dermatol Res 1984; 276: 283-7.
24. Stene MA, Babajanians M, Bhuta S, Cochran AJ. Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 1988; 91: 125-8.
25. Toriyama K, Wen DR, Paul E, Cochran AJ. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 1993; 100: 269S-73S.
26. Shurin MR, Esche C, Lokshin A, Lotze MT. Apoptosis of dendritic cells. In: Thomson AW, ed. Dendritic Cells. San Diego: Academic Press. 1999: 673-92.
27. Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, Lotze MT, Shurin MR. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999; 66: 336-44.
28. Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, Lotze MT, Shurin MR. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 1999; 29: 2148-55.
29. Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000; 83: 506-13.
30. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 2000; 165: 1956-64.
31. Esche C, Shurin GV, Kirkwood JM, Wang GQ, Rabinowich H, Pirtskhalaishvili G, Shurin MR. Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 2001; 7: 974s-9s.
32. Pirtskhalaishvili G, Shurin GV, Esche C, Trump DL, Shurin MR. TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis. Prostate Cancer Prostatic Dis 2001; 4: 221-7.
33. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164: 1269-76.
34. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003; 170: 3488-94.
35. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 2002; 62: 2583-91.
36. Katsenelson NS, Shurin GV, Bykovskaia SN, Shogan J, Shurin MR. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 2001; 14: 40-5.
37. Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K, Tanaka M, Katano M. Dysfunctional and short-lived subsets in monocyte- derived dendritic cells from patients with advanced cancer. Clin Immunol 2002; 105: 286-95.
38. Pinzon-Charry A, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Lopez JA. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2006; 8: R5.
39. Jia JJ, Wang ZN, Liu GX, Wang ZX. [Apoptosis and expression of Fas/FasL in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma]. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 1693-6.
40. Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B, Pantalone D. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol 2006; 121: 74-80.
41. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003; 89: 1463-72.
42. Maecker B, Mougiakakos D, Zimmermann M, Behrens M, Hollander S, Schrauder A, Schrappe M, Welte K, Klein C. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006; 20: 645-9.
43. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999; 31: 323-31.
44. Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12: 3275-82.
45. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006; 55: 151-9.
46. Wojas K, Tabarkiewicz J, Jankiewicz M, Rolinski J. Dendritic cells in peripheral blood of patients with breast and lung cancer--a pilot study. Folia Histochem Cytobiol 2004; 42: 45-8.
47. Shurin GV, Aalamian M, Pirtskhalaishvili G, Bykovskaia S, Huland E, Huland H, Shurin MR. Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 2001; 39 Suppl 4: 37-40.
48. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM, Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001; 61: 363-9.
49. Song EY, Shurin MR, Tourkova IL, Chatta G, Shurin GV. Human renal cell carcinoma inhibits dendritic cell maturation and functions. Urologe A 2004; 43 Suppl 3: S128-30.
50. Shurin MR, Lotze MT. Dendritic Cells in Cancer: Emergence of the Discipline. In: Shurin M and Salter R, Editors. Dendritic cells in cancer. New York: Springer. 2009.
51. Ishida A, Ohta M, Toda M, Murata T, Usui T, Akita K, Inoue M, Nakada H. Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation. Proteomics 2008; 8: 3342-9.
52. Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Peguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 2006; 18: 879-86.
53. Bennaceur K, Popa I, Chapman JA, Migdal C, Peguet-Navarro J, Touraine JL, Portoukalian J. Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells. Glycobiology 2009; 19: 576-82.
54. Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009; 76: 155-62.
55. Chen M, Wang J. Regulation of Immune Responses by Spontaneous and T cell-mediated Dendritic Cell Death. J Clin Cell Immunol 2011;:S3.
56. Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 2008; 57: 1665-73.
57. Ataera H, Hyde E, Price KM, Stoitzner P, Ronchese F. Murine melanoma- infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One 2011; 6: e17515.
58. Alcalay J, Kripke ML. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J Immunol 1991; 146: 1717-21.
59. Halliday GM, Lucas AD, Barnetson RS. Control of Langerhans' cell density by a skin tumour-derived cytokine. Immunology 1992; 77: 13-8.
60. Halliday GM, Reeve VE, Barnetson RS. Langerhans cell migration into ultraviolet light-induced squamous skin tumors is unrelated to anti- tumor immunity. J Invest Dermatol 1991; 97: 830-4.
61. Tas MP, Simons PJ, Balm FJ, Drexhage HA. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 1993; 36: 108-14.
62. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170: 111-9.
63. Chaux P, Moutet M, Faivre J, Martin F, Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996; 74: 975-83.
64. Tourkova IL, Shurin GV, Wei S, Shurin MR. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol 2007; 178: 7787-93.
65. Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by IL-15 of MHC class I antigen- processing machinery in human dendritic cells inhibited by tumor- derived gangliosides. J Immunol 2005; 175: 3045-52.
66. Shurin MR, Yurkovetsky ZR, Tourkova IL, Balkir L, Shurin GV. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer 2002; 101: 61-8.
67. Makarenkova VP, Shurin GV, Tourkova IL, Balkir L, Pirtskhalaishvili G, Perez L, Gerein V, Siegfried JM, Shurin MR. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 2003; 145: 55-67.
68. Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta 2009; 1795: 16-24.
69. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001; 46: 68-75.
70. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-8.
71. Kichler-Lakomy C, Budinsky AC, Wolfram R, Hellan M, Wiltschke C, Brodowicz T, Viernstein H, Zielinski CC. Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur J Med Res 2006; 11: 7-12.
72. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230-7.
73. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D, Eremin O. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004; 53: 510-8.
74. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006; 35: 459-83.
75. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 451-61.
76. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004; 92: 13-27.
77. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73: 309-16.
78. Shurin MR, Naiditch H, Zhong H, Shurin GV. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011; 11: 988-92.
79. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006; 12: 4794-803.
80. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-79.
81. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-22.
82. Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 2006; 146: 189-96.
83. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105: 1162-9.
84. Ma Y, Shurin GV, Gutkin DW, Shurin MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol 2012; 22: 298-306.
85. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919-29.
86. Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012; 61: 223-30.
87. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195: 15-21.
88. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725-31.
89. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002; 195: 221-31.
90. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391-401.
91. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL, Jr., Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-70.
92. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24: 242-8.
93. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor- associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121: 1361-72.
94. Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 2012; 61: 289-93.
95. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011; 186: 6905-13.
96. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 2010; 1: 329-38.